Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. Dizal (Jiangsu) Pharmaceutical Co., Ltd. was founded in 2017 and is based in Shanghai, China.
Frequently asked questions
What sector does Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) operate in?
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) current stock price?
As of the latest data, Dizal (Jiangsu) Pharmaceutical Co. Ltd. A stock price is CN¥57.35, with a previous close of CN¥56.79. Dizal (Jiangsu) Pharmaceutical Co. Ltd. A gained CN¥0.56 in the last trading session, representing a 0.99% increase.
What is Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) current market capitalization?
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A market cap is approximately 26.68 billion.
What is Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) Earnings Per Share (EPS)?
The trailing EPS is -CN¥1.26, and the forward EPS is CN¥0.66.
Does Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) pay dividends?
No. Dizal (Jiangsu) Pharmaceutical Co. Ltd. A does not pay a dividend.
What is Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192) beta (volatility) score?
Dizal (Jiangsu) Pharmaceutical Co. Ltd. A has a beta of -0.012, indicating lower volatility than the overall market.
